Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers

Detalhes bibliográficos
Autor(a) principal: Gümüş,Hatice Hale
Data de Publicação: 2021
Outros Autores: Ödemiş,İlker, Alışka,Hikmet Eda, Karslı,Aslı, Kara,Sibel, Özkale,Murat, Gül,Eylem
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301825
Resumo: SUMMARY OBJECTIVE: This study aims to investigate the antibody response and the side effects of the two-dose inactive SARS-CoV-2 vaccine (CoronaVac, Sinovac, China) among a health care worker population in Turkey. METHODS: This study was a prospective, cross-sectional, single-center study conducted between December 16, 2020, and March 15, 2021. We evaluated the side effects from a questionnaire, and anti-spike immunoglobulin G response to the vaccine (0- and 28-day schedule) using an enzyme-linked immunosorbent assay. RESULTS: A total of 94 of 184 health care workers completed this study. The percentages of participants who were seronegative at baseline and achieved to the seropositivity were 21.3 and 97.9%, respectively, on day 21 after vaccinations. The seropositivity was predominantly detected in 31–45 years of the age group (55.4%, p=0.636), normal body mass index (47.8%, p=0.999), nonsmokers (64.1%, p=0.999), those without any comorbidities (73.9%, p=0.463), and those without any side effects (70.2%, p=0.256). The frequencies of overall side effects within seven days after the first and second doses of CoronaVac were 37.2 and 28.7%, respectively. The most common side effects was localized pain at the injection site (15.7 and 11.6%, respectively). CONCLUSIONS: We found that vaccination by two-dose CoronaVac could elicit a specific humoral response, and it was well tolerated in health care workers. The high seropositivity developed after the second dose attracted attention. Our study will be useful in terms of showing short-term immunity and side effects.
id AMB-1_f2ca3cd8272d484292fd1d936f168a4b
oai_identifier_str oai:scielo:S0104-42302021001301825
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workersCOVID-19PandemicsVaccineAdverse eventsHealth personnelSUMMARY OBJECTIVE: This study aims to investigate the antibody response and the side effects of the two-dose inactive SARS-CoV-2 vaccine (CoronaVac, Sinovac, China) among a health care worker population in Turkey. METHODS: This study was a prospective, cross-sectional, single-center study conducted between December 16, 2020, and March 15, 2021. We evaluated the side effects from a questionnaire, and anti-spike immunoglobulin G response to the vaccine (0- and 28-day schedule) using an enzyme-linked immunosorbent assay. RESULTS: A total of 94 of 184 health care workers completed this study. The percentages of participants who were seronegative at baseline and achieved to the seropositivity were 21.3 and 97.9%, respectively, on day 21 after vaccinations. The seropositivity was predominantly detected in 31–45 years of the age group (55.4%, p=0.636), normal body mass index (47.8%, p=0.999), nonsmokers (64.1%, p=0.999), those without any comorbidities (73.9%, p=0.463), and those without any side effects (70.2%, p=0.256). The frequencies of overall side effects within seven days after the first and second doses of CoronaVac were 37.2 and 28.7%, respectively. The most common side effects was localized pain at the injection site (15.7 and 11.6%, respectively). CONCLUSIONS: We found that vaccination by two-dose CoronaVac could elicit a specific humoral response, and it was well tolerated in health care workers. The high seropositivity developed after the second dose attracted attention. Our study will be useful in terms of showing short-term immunity and side effects.Associação Médica Brasileira2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301825Revista da Associação Médica Brasileira v.67 n.12 2021reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.20210755info:eu-repo/semantics/openAccessGümüş,Hatice HaleÖdemiş,İlkerAlışka,Hikmet EdaKarslı,AslıKara,SibelÖzkale,MuratGül,Eylemeng2021-12-09T00:00:00Zoai:scielo:S0104-42302021001301825Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2021-12-09T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
title Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
spellingShingle Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
Gümüş,Hatice Hale
COVID-19
Pandemics
Vaccine
Adverse events
Health personnel
title_short Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
title_full Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
title_fullStr Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
title_full_unstemmed Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
title_sort Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
author Gümüş,Hatice Hale
author_facet Gümüş,Hatice Hale
Ödemiş,İlker
Alışka,Hikmet Eda
Karslı,Aslı
Kara,Sibel
Özkale,Murat
Gül,Eylem
author_role author
author2 Ödemiş,İlker
Alışka,Hikmet Eda
Karslı,Aslı
Kara,Sibel
Özkale,Murat
Gül,Eylem
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gümüş,Hatice Hale
Ödemiş,İlker
Alışka,Hikmet Eda
Karslı,Aslı
Kara,Sibel
Özkale,Murat
Gül,Eylem
dc.subject.por.fl_str_mv COVID-19
Pandemics
Vaccine
Adverse events
Health personnel
topic COVID-19
Pandemics
Vaccine
Adverse events
Health personnel
description SUMMARY OBJECTIVE: This study aims to investigate the antibody response and the side effects of the two-dose inactive SARS-CoV-2 vaccine (CoronaVac, Sinovac, China) among a health care worker population in Turkey. METHODS: This study was a prospective, cross-sectional, single-center study conducted between December 16, 2020, and March 15, 2021. We evaluated the side effects from a questionnaire, and anti-spike immunoglobulin G response to the vaccine (0- and 28-day schedule) using an enzyme-linked immunosorbent assay. RESULTS: A total of 94 of 184 health care workers completed this study. The percentages of participants who were seronegative at baseline and achieved to the seropositivity were 21.3 and 97.9%, respectively, on day 21 after vaccinations. The seropositivity was predominantly detected in 31–45 years of the age group (55.4%, p=0.636), normal body mass index (47.8%, p=0.999), nonsmokers (64.1%, p=0.999), those without any comorbidities (73.9%, p=0.463), and those without any side effects (70.2%, p=0.256). The frequencies of overall side effects within seven days after the first and second doses of CoronaVac were 37.2 and 28.7%, respectively. The most common side effects was localized pain at the injection site (15.7 and 11.6%, respectively). CONCLUSIONS: We found that vaccination by two-dose CoronaVac could elicit a specific humoral response, and it was well tolerated in health care workers. The high seropositivity developed after the second dose attracted attention. Our study will be useful in terms of showing short-term immunity and side effects.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301825
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302021001301825
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1806-9282.20210755
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.67 n.12 2021
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212836971642880